AI Engines For more Details: Perplexity Kagi Labs You
Respiratory Stimulation: Bemegride has respiratory stimulant properties, meaning it can increase respiratory rate and depth. This effect can be beneficial in treating respiratory depression caused by central nervous system depressants such as barbiturates.
Antidote for Barbiturate Overdose: Bemegride has been used as an antidote for barbiturate overdose. Barbiturates are central nervous system depressants that can lead to respiratory depression and potentially fatal overdose. Bemegride's ability to stimulate respiration can help counteract the respiratory depression caused by barbiturates.
Central Nervous System Stimulation: Bemegride acts as a central nervous system stimulant, leading to increased alertness, wakefulness, and overall arousal. This effect can be useful in treating conditions characterized by central nervous system depression or sedation.
Historical Use in Narcolepsy: In the past, bemegride was sometimes used in the treatment of narcolepsy, a neurological disorder characterized by excessive daytime sleepiness and sudden onset of sleep. Its stimulant properties were thought to help promote wakefulness and reduce episodes of daytime sleepiness in individuals with narcolepsy.
Side Effects: Common side effects of bemegride may include restlessness, insomnia, anxiety, tremors, palpitations, and gastrointestinal disturbances. In high doses or with prolonged use, bemegride may increase the risk of adverse effects such as tachycardia (rapid heart rate), hypertension (high blood pressure), and seizures.
Limited Clinical Use: Bemegride is no longer widely used in clinical practice, and its use has largely been replaced by other medications with similar therapeutic effects but fewer side effects and risks. Its historical use as a respiratory stimulant and antidote for barbiturate overdose has largely been superseded by safer and more effective alternatives.
Regulatory Status: The use of bemegride may be restricted or prohibited in some countries due to concerns about its safety profile and limited therapeutic benefits compared to other medications. Healthcare providers should exercise caution when considering the use of bemegride and carefully weigh the potential risks and benefits for individual patients.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 0.8 | 0.3 | 1.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergies | 0.3 | 0.6 | -1 |
| Allergy to milk products | 0.6 | 0.6 | |
| Alzheimer's disease | 0.6 | 1.6 | -1.67 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.3 | 0.67 |
| Ankylosing spondylitis | 0.3 | 0.6 | -1 |
| Anorexia Nervosa | 0.3 | 1.1 | -2.67 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.3 | -2 |
| Asthma | 0.8 | 0.5 | 0.6 |
| Atherosclerosis | 0.3 | 0.7 | -1.33 |
| Atrial fibrillation | 0.9 | 0.3 | 2 |
| Autism | 1.1 | 1.9 | -0.73 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Bipolar Disorder | 0.6 | 1.1 | -0.83 |
| Brain Trauma | 0.8 | -0.8 | |
| Breast Cancer | 0.3 | 0.3 | 0 |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.1 | 0.9 | -8 |
| Cerebral Palsy | 0.8 | -0.8 | |
| Chronic Fatigue Syndrome | 0.6 | 0.9 | -0.5 |
| Chronic Kidney Disease | 1.4 | -1.4 | |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 1.1 | -2.67 |
| Coagulation / Micro clot triggering bacteria | 0.8 | -0.8 | |
| Cognitive Function | 0.8 | 0.5 | 0.6 |
| Colorectal Cancer | 0.8 | 0.5 | 0.6 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 0.3 | 0.8 | -1.67 |
| COVID-19 | 0.3 | 1.7 | -4.67 |
| Crohn's Disease | 1.4 | 1.6 | -0.14 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 1.1 | 0.8 | 0.38 |
| Depression | 1.7 | 1.8 | -0.06 |
| Endometriosis | 0.3 | 1.4 | -3.67 |
| Fibromyalgia | 0.5 | 0.2 | 1.5 |
| Functional constipation / chronic idiopathic constipation | 1 | 1.1 | -0.1 |
| gallstone disease (gsd) | 0.3 | 0.5 | -0.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.3 | 0.8 | -1.67 |
| Gout | 0.3 | 0.6 | -1 |
| Graves' disease | 0.3 | 1.1 | -2.67 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.8 | 0.6 | 0.33 |
| Heart Failure | 0.8 | 0.8 | 0 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.6 | 1.6 | -1.67 |
| Hypothyroidism | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.3 | 0.7 | -1.33 |
| Inflammatory Bowel Disease | 1.9 | -1.9 | |
| Insomnia | 0.3 | 1.1 | -2.67 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 0.8 | 1.4 | -0.75 |
| ischemic stroke | 0.3 | 0.5 | -0.67 |
| Liver Cirrhosis | 1.4 | 1.4 | 0 |
| Long COVID | 0.5 | 2.2 | -3.4 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | 0.3 | 0 |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.2 | -0.2 | |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 1.5 | 1.4 | 0.07 |
| Mood Disorders | 1.7 | 1.7 | 0 |
| Multiple Sclerosis | 0.6 | 1.3 | -1.17 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.8 | -0.8 | |
| Neuropathy (all types) | 0.5 | -0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 1.4 | -0.27 |
| Obesity | 1.7 | 1.4 | 0.21 |
| obsessive-compulsive disorder | 0.6 | 0.3 | 1 |
| Osteoarthritis | 0.3 | -0.3 | |
| Osteoporosis | 0.8 | 0.8 | |
| Parkinson's Disease | 1.4 | 1.6 | -0.14 |
| Polycystic ovary syndrome | 1.4 | 1.4 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.6 | -0.6 | |
| Psoriasis | 0.3 | 0.8 | -1.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2 | 0.8 | 1.5 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 1.2 | 1.4 | -0.17 |
| scoliosis | 0.3 | 0.8 | -1.67 |
| Sleep Apnea | 0.9 | 1.1 | -0.22 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.8 | -0.6 |
| Systemic Lupus Erythematosus | 0.6 | 1.1 | -0.83 |
| Tic Disorder | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.9 | 1.1 | -0.22 |
| Type 2 Diabetes | 1.4 | 1.1 | 0.27 |
| Ulcerative colitis | 0.3 | 1.4 | -3.67 |
| Unhealthy Ageing | 0.6 | 0.8 | -0.33 |
| Vitiligo | 0.6 | 0.2 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
